Lexaria Bioscience Patented Hemp Technology

Lexaria is a biotech company with patented lipid-based delivery technology that enhances taste and absorption of beneficial molecules like CBD and THC …

Lexaria Bioscience Patented Hemp Technology

© 2020 www.B-TV.com. All Rights Reserved.

Lexaria is a biotech company with patented lipid-based delivery technology that enhances taste and absorption of beneficial molecules like CBD and THC found in cannabis edible products. And we also have our own line of products that are hemp-based products.

Lexaria Bioscience Corp. is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company’s lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also masking taste.

Cannabinoids are poorly absorbed by the body’s gastrointestinal tract and consumers often default to alternate routes of administration like smoking to achieve higher effectiveness.

The Company’s technology is patent-protected for cannabidiol (CBD) and all other non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol (THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

Lexaria’s propiertary technology delivers the following advantages for cannabinoid edibles:

Masks taste – eliminates the strong tastes in cannabinoid edibles, enabling zero-sugar formats.
Reduces time of onset – effects are felt within 15-20 min vs. 60-120 min.
Increases bio-absorption – by 5 – 10X, to equate or excel that of inhalation.

For more information on Lexaria Bioscience (Nasdaq: LEXX) please fill out the form below.

You might also like

Ivan Bebek on Where the Biggest Mining Returns May Still Lie
Metals & Mining
March 4, 2026

Ivan Bebek on Where the Biggest Mining Returns May Still Lie

Veteran mining entrepreneur Ivan Bebek believes the current gold and silver cycle may only be getting started.

This is some text inside of a div block.
Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine
Health & Wellness
March 3, 2026

Picard Medical / SynCardia Tackling One of the Largest Unmet Needs in Cardiovascular Medicine

Advanced heart failure continues to rise globally, while the supply of donor hearts remains limited. This structural imbalance creates a significant and expanding market opportunity, with thousands of patients each year lacking viable treatment options and placing growing economic pressure on healthcare systems.

This is some text inside of a div block.
BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs
ETFs
March 3, 2026

BMO ETFs Highlights Simplicity and Low Cost in Asset Allocation ETFs

In Canada, management fees for asset allocation ETFs can range from approximately 50 basis points down to 15 basis points.

This is some text inside of a div block.
Subscribe and receive the investor Info